### Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 3

#### LA JOLLA PHARMACEUTICAL CO

Form 3 May 22, 2006

# FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### OMB APPROVAL

OMB Number: 3235-0104

Expires: January 31, 2005

0.5

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, response...
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person \* Statement LA JOLLA PHARMACEUTICAL CO [LJPC] KOCH LISA I (Month/Day/Year) 05/18/2006 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) 6455 NANCY RIDGE DRIVE (Check all applicable) (Street) 6. Individual or Joint/Group Filing(Check Applicable Line) 10% Owner Director \_X\_ Form filed by One Reporting \_X\_\_ Officer Other Person (give title below) (specify below) SAN DIEGO, CAÂ 92121 Form filed by More than One Sr Dir Regulatory Affairs Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 2. Amount of Securities 4. Nature of Indirect Beneficial 1. Title of Security Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (I) (Instr. 5) D Â Common Stock 10,974 Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

currently valid OMB control number.

1. Title of Derivative Security (Instr. 4)	2. Date Exer Expiration I (Month/Day/Year)	Date			4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of	Derivative Security	Security: Direct (D) or Indirect	

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 3

				Shares		(I) (Instr. 5)	
Stock Options (right to buy)	(1)	09/30/2012	Common Stock	1,600	\$ 21.3	D	Â
Stock Options (right to buy)	(2)	11/21/2012	Common Stock	600	\$ 29.5	D	Â
Stock Options (right to buy)	(2)	05/12/2013	Common Stock	2,400	\$ 14.85	D	Â
Stock Options (right to buy)	(2)	09/18/2013	Common Stock	2,400	\$ 23.55	D	Â
Stock Options (right to buy)	(3)	05/21/2014	Common Stock	3,999	\$ 14.8	D	Â
Stock Options (right to buy)	(2)	04/25/2015	Common Stock	3,307	\$ 2.4	D	Â
Stock Options (right to buy)	(2)	05/19/2015	Common Stock	1,692	\$ 2.15	D	Â
Stock Options (right to buy)	(2)	10/10/2015	Common Stock	14,500	\$ 4.2	D	Â
Stock Options (right to buy)	(2)	04/17/2016	Common Stock	89,321	\$ 4.46	D	Â

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
1	Director	10% Owner	Officer	Other		
KOCH LISA I 6455 NANCY RIDGE DRIVE SAN DIEGO, CA 92121	Â	Â	Sr Dir Regulatory Affairs	Â		

## **Signatures**

/s/ Gail A. Sloan Attorney-in-fact for Lisa I.
Koch
05/22/2006

\*\*Signature of Reporting Person

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 1/3 of the stock options vested and became exercisable on 9/30/2003. Thereafter, 1/24th of the remainder of the options began to vest and become exercisable each month.

Date

- (2) 1/36 of the stock options vest and become exercisable each month following the grant date.
- (3)

  1/2 of the options vest on the date that the Company receives approval to market its lead drug candidate for the treatment of lupus and 1/24 of the remaining options vest at the end of each month thereafter until all of the options are vested. Notwithstanding the foregoing, if marketing approval is not obtained between the grant date and the three year anniversary of the grant date, then 100% of the options will vest on the three year anniversary of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Reporting Owners 2

### Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 3

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.